An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease-Reference-Cited by-同舟云学术

An Observational Study of Reduction in Glycemic Parameters and Liver Stiffness by Saroglitazar 4 mg in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

Published:2020-07-08 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Mitra Asis

Publisher

Cureus, Inc.

Subject

Aerospace Engineering

Reference23 articles.

1. IDF Diabetes Atlas Regional Fact Sheet. (2020). Accessed. July 2, 2020: http://diabetesatlas.org/upload/resources/2019/2019_regional_factsheet.pdf.

2. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States;Wong RJ;Gastroenterology,2015

3. Association of nonalcoholic fatty liver disease with insulin resistance;Marchesini G;Am J Med,1999

4. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study;Williams CD;Gastroenterology,2011

5. Non-Alcoholic Fatty Liver Disease: Assessment and Management (NICE Guideline #49);National Guideline Centre (UK),2016

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD;Metabolism;2024-06

2. The role of peroxisome proliferator‐activated receptors in the regulation of bile acid metabolism;Basic & Clinical Pharmacology & Toxicology;2023-12-15

3. A Study to Evaluate the Efficacy of Saroglitazar in Non-Alcoholic Steatohepatitis Induced by High Fructose Diet Rat Model;Journal of Pharmacology and Pharmacotherapeutics;2023-12-09

4. Saroglitazar in Non-alcoholic Fatty Liver Disease From Bench to Bedside: A Comprehensive Review and Sub-group Meta-Analysis;Cureus;2023-10-22

5. Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease;Medicina;2023-10-08